Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2015
At a glance
- Drugs Exemestane (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 23 Dec 2014 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019 as reported by ClinicalTrials.gov record.
- 09 Jul 2013 Planned end date changed from 1 Jun 2015 to 1 Jun 2017 as reported by ClinicalTrials.gov.
- 06 Feb 2012 Results published in Lancet Oncology.